Zobrazeno 1 - 10
of 14
pro vyhledávání: '"63"'
Autor:
Musa Mayer, Mary Beattie, Sara A. Hurvitz, Adam Brufsky, Bongin Yoo, Denise A. Yardley, Hope S. Rugo, Mohammad Jahanzeb, Sandra M. Swain, Peter A. Kaufman, Joyce O'Shaughnessy, Ginny Mason, Debu Tripathy, Melody A. Cobleigh
Publikováno v:
Cancer Research. 75:P3-07
Introduction The Systemic Therapies for HER2-Positive Metastatic Breast Cancer Registry (SystHERs) is a US-based prospective observational cohort study currently enrolling patients with HER2-positive metastatic breast cancer (MBC). It began in 2012 a
Autor:
Whitney C Rhodes, Amin Haiderali, Lee S. Schwartzberg, Min Huang, Jan Sieluk, Santosh Gautam, Karen E Skinner
Publikováno v:
Cancer Research. 81:PS13-42
Background: Recurrence is common among patients with early-stage triple-negative breast cancer (ESTNBC). There is minimal real-world evidence describing the patient characteristics and clinical outcomes following recurrence among patients receiving n
Autor:
D Zajchowski, S-A Im, Darren W. Davis, Ute Hoch, S Sy, J. Cortes, Joyce A. O'Shaughnessy, Katie Caygill, E. A. Perez, L Lu, Alison L. Hannah, Chris Twelves, Ahmad Awada, HS Rugo
Publikováno v:
Cancer Research. 76:P1-13
Background: Etirinotecan pegol (EP) is a long-acting Top1 inhibitor providing sustained levels of active metabolite throughout the entire chemotherapy cycle. The phase 3 BEACON trial compared EP to treatment of physician's choice (TPC) in patients wi
Autor:
V McNally, Sarah Heeson, Bongin Yoo, L. Gianni, A Stein, C Portera, Andreas Schneeweiss, JC Cortes, Sandra M. Swain, J. Baselga
Publikováno v:
Cancer Research. 76:P4-14
BACKGROUND: Pertuzumab (P) in combination with trastuzumab (T) and docetaxel (D) is the approved first line SOC in patients with HER2 positive metastatic breast cancer and is approved neoadjuvantly in patients with HER2 positive stage Ib-IIIc breast
Autor:
Svetislava J. Vukelja, K Logie, Jerome H. Goldschmidt, Kristi McIntyre, AR Kumar, Joanne L. Blum, Joyce A. O'Shaughnessy, Lina Asmar, N Wu, CR Osborne, Yu-Sen Wang, Devchand Paul, Frankie A. Holmes, IJ Sanchez, DL Lindquist, Me Lee
Publikováno v:
Cancer Research. 73:S3-07
Introduction Dasatinib inhibits the protein tyrosine kinase, Src, which can support the development of bone metastases in patients with ER+ breast cancer. The primary objective of this study is to determine if letrozole plus dasatinib increases the c
Publikováno v:
Cancer Research. 73:P4-12
Background: CLEOPATRA is a phase III study of placebo (Pla)+T+D and P+T+D in HER2-positive first-line MBC. The combination of both HER2-targeted antibodies, P+T, with D resulted in significantly improved progression-free survival (PFS) and overall su
Publikováno v:
Cancer Research. 71:P3-14
Background Breast cancer is the most common malignancy in females in Europe and is the most common cause of cancer mortality in women, with doxorubicin playing an important role in chemotherapy (CT) regimens used in this setting but limited by cardio
Autor:
P. Berardi, Lisa Vandermeer, Angel Arnaout, Mark Clemons, D. Mirsky, J-M Caudrelier, Martin Chasen, S. Samiee, Susan Dent, Nathaniel Bouganim
Publikováno v:
Cancer Research. 71:P2-15
Background: Approximately 10% of new breast cancer patients will present with overt synchronous metastatic disease. Controversy exists about the optimal local management of these patients. While several series suggest that removal of primary tumour i
Publikováno v:
Cancer Research. 70:P1-09
Objectives: Estimate the healthcare costs before and after progression to chemotherapy in a population of post-menopausal hormone-receptor positive (HR+) metastatic breast cancer (mBC) patients. Methods: This retrospective cohort study used claims fr
Autor:
Ebenezer A. Kio, Gregory A. Masters, W. Thomas Purcell, Bryan J. Schneider, Robert M. Sharkey, Pius Maliakal, William A. Wegener, Michael J. Guarino, Charles J. Schneider, Serengulam V. Govindan, Boyd Mudenda, Leena Gandhi, D. Ross Camidge, Tirrell Johnson, Jamal Misleh, Allyson J. Ocean, Rebecca S. Heist, Kevin Kalinsky, David M. Goldenberg, Jhanelle E. Gray, Alexander Starodub
Publikováno v:
Cancer Research. 77:CT155-CT155
Introduction: Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) delivering SN-38, a topoisomerase-1 inhibitor, to mSCLC cells expressing Trop-2. We are studying the safety/tolerability and efficacy of IMMU-132 in patients with rela